WO1996005817A1 - Medicament for treatment or prophylaxis of incontinence - Google Patents
Medicament for treatment or prophylaxis of incontinence Download PDFInfo
- Publication number
- WO1996005817A1 WO1996005817A1 PCT/GB1995/001995 GB9501995W WO9605817A1 WO 1996005817 A1 WO1996005817 A1 WO 1996005817A1 GB 9501995 W GB9501995 W GB 9501995W WO 9605817 A1 WO9605817 A1 WO 9605817A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- incontinence
- compound
- pharmaceutically acceptable
- amino
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
Definitions
- the present invention relates to the treatment of incontinence disorders, and in particular to a new medical use for azapirones, and other compounds which interact with 5-HT1A receptors, in the treatment of urinary and fecal incontinence and related conditions.
- the condition of incontinence is typified by the inappropriate flow of fluids in passages and from natural orifices of the body and includes both the flow of material from the body, for example in urinary and fecal inconvenience, and the retention of material in the body, for example in urinary retention.
- Pharmacologic drugs in use include those directed towards improving stability of the detrusor muscle in the bladder wall (and thus bladder capacity) by blocking cholinergic transmission and those having a direct inhibitory effect on the smooth muscle of the bladder wall.
- Examples include anticholinergics (which suppress urgency and urgency incontinence as well as being useful in the treatment of neurogenic
- incontinence such as belladonna, propantheline bromide, methantheline bromide, baclophene, prazocine and
- Urethral resistance may be improved by alpha agonists.
- alpha agonists include phenylpropanolamine,
- ephedrine ephedrine
- imipramine ephedrine
- Parasymphathomimetics e.g. Urecholine
- Most clinicians find, however, that significant improvement in bladder
- fecal incontinence may result from failure of voluntary control of rectal sphincters with involuntary passage of feces and flatus which may be due to anatomic disruption of the
- sphincters resulting from previous surgery, obstetric trauma, or other injuries.
- Neurologic problems are primary in other patients with anatomically intact sphincters. Procidentia is often associated with incontinence if it remains untreated for long periods.
- operant conditioning is used to overcome incontinence.
- Various operations have been proposed for improving the function of intact sphincters, but the results are mixed.
- Elderly patients generally are prone to failure of the repair or prompt recurrence of incontinence.
- Incontinence is a distressing condition which may severely incapacitate or stigmatize the sufferer.
- present treatments are not entirely satisfactory since they may either not be effective on all types of incontinence, or they may involve invasive or unpleasant procedures such as surgery or nerve stimulation.
- the azapirone class of psychotropic drugs compounds is particularly effective in relieving the symptoms of urinary and fecal incontinence and, accordingly are of benefit in the treatment or prophylaxis of urinary and fecal incontinence and other related disorders.
- invention provides the use of an azapirone or a
- the most notable members of the class include buspirone, ipsapirone, gepirone and tandospirone, although a range of other azapirone compounds and derivatives have also been described (see for example EP-A-0356997, EP-A-0442424, EP-A-303951, EP-A-455510, US-A-4, 818, 756, EP-A-0129128 and EP-A-082402). All such compounds and derivatives are included within the scope of this invention, as are all their pharmaceutically acceptable salts, including both organic and inorganic salts (eg. with alkali and alkaline earth metal, ammonium, ethanolamine, diethanolamine and meglumine, chloride, hydrogen carbonate, phosphate, sulphate and acetate counterions). Appropriate pharmaceutically acceptable salts are well described in the
- Compounds interacting with 5-HT1A receptors which may be used according to the invention include agonists, partial agonists and antagonists.
- Receptor agonists are defined as those compounds capable of binding to the receptor and directly activating its activity.
- Receptor antagonists bind to the receptor and block or inhibit its biological activity.
- Partial agonists both up- regulate and down-regulate the receptor and may exhibit both pre-synaptic and post-synaptic effects. Generally speaking, partial agonists directly activate the
- concentration and dissociation of the ligand-receptor complex is also known to those skilled in the art. For example, see Cheng et al., Biochemical Pharmacology, 22, 3099-3108 (1973); and Taylor et al., Life Sciences, 41, 1961-1969 (1987). Likewise 5-HT1A antagonist activity may also be easily determined and assayed (see for example J. Pharmacol. Exp. Ther. 238. 248-253 (1986) and J. Pharmacol. Exp. Ther. 258, 58-65 (1991).
- N-arylpiperazines including, inter alia, those
- salts and solvates of such compounds may readily be prepared using counterions and techniques well known in the art. All such salts and solvates as well as any isomers (eg. stereoisomers and/or enantiomers) and their mixtures are all included according to the invention.
- aspects of the invention accordingly provide a method of treatment of the human or non-human animal body to combat incontinence disorders, said method comprising administering to said body a compound
- 5-HT1A receptors interacting with 5-HT1A receptors, or a pharmaceutically acceptable salt thereof.
- the term “combat” includes both therapy and prophylaxis, in particular of individuals with a history of, or at risk from, incontinence
- compositions may comprise an azapirone or a pharmaceutically acceptable salt thereof.
- compositions may comprise from about 0.1% to about 99% by weight of the formulation.
- pharmaceutically acceptable is meant that the ingredient must be compatible with other ingredients of the compositions as well as
- Suitable carriers, excipients, and diluents are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, aglinates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, water, water/ethanol, water/ glycol, water/polyethylene, glycol, propylene glycol, methyl cellulose, methylhydroxybenzoates, propyl
- a tablet is prepared using the ingredients below:
- Tablets each containing 60 mg of active ingredient, are made as follows:
- buspirone was administered for a total period of 4 months, without relapse of the patient's urinary symptoms.
Abstract
The present invention relates to the use of compounds which interact with 5-HT1A receptors, especially azapirones or pharmaceutically acceptable salts thereof, for the preparation of medicaments for use in the treatment or prophylaxis of incontinence disorders, methods of treatment using these compounds and pharmaceutical compositions containing these compounds.
Description
MEDICAMENT FOR TREATMENT OR PROPHYLAXIS OF INCONTINENCE
The present invention relates to the treatment of incontinence disorders, and in particular to a new medical use for azapirones, and other compounds which interact with 5-HT1A receptors, in the treatment of urinary and fecal incontinence and related conditions.
The condition of incontinence is typified by the inappropriate flow of fluids in passages and from natural orifices of the body and includes both the flow of material from the body, for example in urinary and fecal inconvenience, and the retention of material in the body, for example in urinary retention.
Urinary incontinence may occur as the result of a number of medical conditions including the failure of voluntary control of vesical and urethral sphincters with constant or frequent involuntary passage of urine. Urinary incontinence conditions include active
incontinence, intermittent incontinence, overflow incontinence, paradoxical incontinence, paralytic incontinence, stress incontinence and passive
incontinence.
Treatment of urinary incontinence is in essence dependent on its type and severity. Generally speaking, there are three approaches, namely the use of
pharmacologic agents, electrical stimulation, or
surgery, the latter two being directed almost
exclusively to the treatment of sphincters of the urogenital tract.
The pharmocological approach is directed primarily to increasing the capacity of incontinent patients to store urine. Pharmacologic drugs in use include those directed towards improving stability of the detrusor muscle in the bladder wall (and thus bladder capacity) by blocking cholinergic transmission and those having a
direct inhibitory effect on the smooth muscle of the bladder wall. Examples include anticholinergics (which suppress urgency and urgency incontinence as well as being useful in the treatment of neurogenic
incontinence) such as belladonna, propantheline bromide, methantheline bromide, baclophene, prazocine and
terodiline and the antimuscarinic agents oxybutynin, flavoxate hydrochloride and the antidepressant
imipramine hydrochloride. The side-effects for all anticholinergics include dry mouth, visual blurring and decreased gastrointestinal motility with resulting constipation.
Urethral resistance may be improved by alpha agonists. Examples include phenylpropanolamine,
ephedrine, and imipramine. Parasymphathomimetics (e.g. Urecholine) have been used with limited success in improving detrusor function. Most clinicians find, however, that significant improvement in bladder
contractility requires such high doses of Urecholine that the side effects (gastrointestinal disturbance) become prohibitive.
The sympathetic nervous system exercises important control over the bladder and urethra. Since the bladder neck and proximal urethra contain mainly alpha- adrenergic receptors, alpha-adrenergic stimulation of the smooth muscle in these areas increases urethral resistance. Sympathomimetic agents that stimulate alpha-adrenergic receptors have been used to treat stress urinary incontinence (SUI) and include ephedrine, pseudoephedrine hydrochloride and phenylpropanolamine hydrochloride. Although these agents may be useful in patients with mild SUI, surgical correction is often preferable to chronic medication with its associated side-effects such as increased irritability, cardiac palpitations, anxiety and drowsiness. Moreover, none of these drugs cure severe SUI. Nerve stimulation may be used as an alternative treatment. Finally the operative
approach may be employed.
As with urinary incontinence, fecal incontinence may result from failure of voluntary control of rectal sphincters with involuntary passage of feces and flatus which may be due to anatomic disruption of the
sphincters resulting from previous surgery, obstetric trauma, or other injuries. Neurologic problems are primary in other patients with anatomically intact sphincters. Procidentia is often associated with incontinence if it remains untreated for long periods. In patients whose sphincters are anatomically intact, operant conditioning is used to overcome incontinence. Various operations have been proposed for improving the function of intact sphincters, but the results are mixed. Elderly patients generally are prone to failure of the repair or prompt recurrence of incontinence.
Incontinence is a distressing condition which may severely incapacitate or stigmatize the sufferer. As can be seen from the above, present treatments are not entirely satisfactory since they may either not be effective on all types of incontinence, or they may involve invasive or unpleasant procedures such as surgery or nerve stimulation. Clearly, any new
treatment which helps to relieve or improve symptoms in such patients in a simple and non-invasive manner would be of benefit.
Surprisingly, it has now been found that the azapirone class of psychotropic drugs compounds is particularly effective in relieving the symptoms of urinary and fecal incontinence and, accordingly are of benefit in the treatment or prophylaxis of urinary and fecal incontinence and other related disorders.
Thus, according to one aspect, the present
invention provides the use of an azapirone or a
pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment or prophylaxis of incontinence disorders.
Azapirones are a novel class of drugs, known primarily for their neurological properties and
demonstrate dopaminergic, noradrenergic and serotonin (5-hydroxy-tryptamine, 5-HT)-modulating effects without untoward side effects (see for example "Symposium on azapirones: a novel class of broad spectrum psychotropic agents 9.12.1989, USA; J. Clin. Psychopharm. 1990, 10(3) suppl.) Their primary use has been in the treatment of anxiety and depression, but more recently other uses have been proposed, for example in the treatment of sexual dysfunction (US-A-4, 640, 921), alcoholism (EP-A- 0303951), motion sickness and chemically-induced emesis (US-A-4, 943,428), cognitive disorders (WO 93/04681) and drug abuse (EP-A-0356997).
Generally speaking, azapirones may be defined as a class of compounds containing a 1,3-bisoxacyclo-2- azaalkane ring optionally containing other ring
heteroatoms eg. sulphur.
The most notable members of the class include buspirone, ipsapirone, gepirone and tandospirone, although a range of other azapirone compounds and derivatives have also been described (see for example EP-A-0356997, EP-A-0442424, EP-A-303951, EP-A-455510, US-A-4, 818, 756, EP-A-0129128 and EP-A-082402). All such compounds and derivatives are included within the scope of this invention, as are all their pharmaceutically acceptable salts, including both organic and inorganic salts (eg. with alkali and alkaline earth metal, ammonium, ethanolamine, diethanolamine and meglumine, chloride, hydrogen carbonate, phosphate, sulphate and acetate counterions). Appropriate pharmaceutically acceptable salts are well described in the
pharmaceutical literature. In addition, some of these salts may form solvates with water or organic solvents such as ethanol. Such solvates are also included within the scope of this invention .
Azapirones are partial agonists at 5-HT1A
receptors. Over the last few years it has become apparent that the ligand for these receptors, namely serotonin (5-HT) is associated directly or indirectly with a number of physiological phenomena, including appetite, memory, thermoregulation, sleep, sexual behaviour, anxiety, depression, and hallucinogenic behaviour (see Glennon, J. Med. Chem. 30 , 1 (1987)).
5-HT receptors have been identified in the central nervous system (CNS; brain and spinal cord) and in peripheral tissues including the gastrointestinal tract, lung, heart, blood vessels, and various other smooth muscle tissues. Multiple types of 5-HT receptors have been recognized. These receptors have been classified as 5-HT1, 5-HT2, and 5-HT3 with at least the 5-HT1 receptor being further divided into sub-classes 5-HT1A, 5-HT1B, 5-HT1C, and 5-HT1D.
The primary focus of research efforts surrounding the biochemistry and physiology of serotonin and
serotonin agonists has been directed toward the CNS, and in particular to the brain. It has also been identified that 5-HT receptors in smooth muscle of the
gastrointestinal tract mediate contraction of this tissue. In EP-455510 it has been disclosed that 5-HT1A agonists inhibit the secretion of gastric acid.
While not wishing to be limited by theory, it appears that the therapeutic effect on incontinence disorders may involve the activity of azapirones
directly on 5-HT1A receptors of the target organs, or possibly the small number of 5-HT1A receptors found in nerve fibres connecting these organs to the autonomic nerve system.
Viewed from a further aspect therefore, the present invention can be seen to provide use of a compound which interacts with 5-HT1A receptors, or a pharmaceutically acceptable salt thereof for the preparation of a
medicament for use in the treatment or prophylaxis of incontinence disorders.
Compounds interacting with 5-HT1A receptors which may be used according to the invention include agonists, partial agonists and antagonists. Receptor agonists are defined as those compounds capable of binding to the receptor and directly activating its activity. Receptor antagonists bind to the receptor and block or inhibit its biological activity. Partial agonists both up- regulate and down-regulate the receptor and may exhibit both pre-synaptic and post-synaptic effects. Generally speaking, partial agonists directly activate the
receptor, but produce a smaller maximal effect. A wide range of such compounds are well known and widely described in the literature.
Procedures for performing binding assays to
determine 5-HT1A agonist activity are known to those skilled in the art and include, for example, the
techniques described in Wong et al., Life Sciences, 46, 231-235 (1990) and the references cited therein. The relationship between apparent binding affinity (K1) as a function of inhibitor IC50 values, radioligand
concentration and dissociation of the ligand-receptor complex is also known to those skilled in the art. For example, see Cheng et al., Biochemical Pharmacology, 22, 3099-3108 (1973); and Taylor et al., Life Sciences, 41, 1961-1969 (1987). Likewise 5-HT1A antagonist activity may also be easily determined and assayed (see for example J. Pharmacol. Exp. Ther. 238. 248-253 (1986) and J. Pharmacol. Exp. Ther. 258, 58-65 (1991).
In addition to the azapirones, 5-HT1A agonists and partial agonists include the following classes of compounds which may be used according to the present invention:
1) 2-amino-1,2,3,3,4-tetrahydronaphthalenes and 3- amino chromanes;
2) 4-amino-1,3,4,5-tetrahydrobenz-[c,d]indoles;
3) non-endogenous indoles;
4) aryloxy propanolamines;
5) benzodioxanes;
6) phenylcyclopropylamines;
7) piperidinylmethyl tetrahydroisoquinolines; and
8) N-arylpiperazines (including, inter alia, those
which are azapirones).
Such compounds are described in more detail in EP- A-0455510 and the references cited therein.
WO93/04681 describes a range of suitable partial agonists and antagonists, which, in addition to the azapirones, include:
1) piperazine derivatives such as 1-[10,11-dihydro-8- (methylthio)-dibenzo [b, f] thiepin-10-yl]-4- methylpiperazine (Methiothepin);
2) 1,1-diethyl-3- (8a-ergolinyl) urea derivatives such as Lisuride (die Vivo and Maayani, J. Pharmacol, Exp. Ther. 238, 248-253) und Terguride (for example Kehr, Eur. J. Pharmacol. 97, 111-119 (1984));
3) 2-amino-tetralines such as 5-fluoro-8-hydroxy-2- (dipropylamino)-tetraline (J. Med. Chem. 33, 1541- 1544 (1990)) and Spiperon (8-[3-(p- fluobenzoyl) propyl]-1-phenyl-1,3,8- triazaspiro [4, 5] decan-4-one).
As mentioned above, pharmaceutically acceptable salts and solvates of such compounds may readily be prepared using counterions and techniques well known in the art. All such salts and solvates as well as any isomers (eg. stereoisomers and/or enantiomers) and their mixtures are all included according to the invention.
Incontinence disorders which may be treated
according to the present invention, include all those in which inappropriate flux of fluid occurs in passages or from natural orifices of the animal body. Typically, incontinence disorders may be associated with conditions
of the gastrointestinal and urogenital tracts which include for example urinary and fecal incontinence and urinary retention.
Other aspects of the invention accordingly provide a method of treatment of the human or non-human animal body to combat incontinence disorders, said method comprising administering to said body a compound
interacting with 5-HT1A receptors, or a pharmaceutically acceptable salt thereof.
More particularly, the invention provides a method of treatment of the human or non-human animal body to combat incontinence disorders, said method comprising administering to said body an azapirone or a
pharmaceutically acceptable salt thereof.
As used herein, the term "combat" includes both therapy and prophylaxis, in particular of individuals with a history of, or at risk from, incontinence
disorders.
The compounds useful in practising the invention are preferably formulated prior to administration. The present invention therefore also provides a
pharmaceutical composition for use in the treatment or prophylaxis of incontinence disorders, said composition comprising a compound interacting with 5-HT1A receptors or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient.
In one preferred embodiment, such compositions may comprise an azapirone or a pharmaceutically acceptable salt thereof.
The active ingredient in such compositions may comprise from about 0.1% to about 99% by weight of the formulation. By "pharmaceutically acceptable" is meant that the ingredient must be compatible with other ingredients of the compositions as well as
physiologically acceptable to the recipient.
Pharmaceutical compositions for use according to
the present invention may be formulated in conventional manner using readily available ingredients, for example as described in any of the afore-mentioned patent specifications. Thus, the active ingredient may be incorporated, optionally together with other active substances, with one or more conventional carriers, diluents and/or excipients, to produce conventional galenic preparations such as tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments, soft and hard gelatin capsules, suppositories, sterile injectable solutions sterile packaged powders, and the like.
Examples of suitable carriers, excipients, and diluents are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, aglinates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, water, water/ethanol, water/ glycol, water/polyethylene, glycol, propylene glycol, methyl cellulose, methylhydroxybenzoates, propyl
hydroxybenzoates, talc, magnesium stearate, mineral oil or fatty substances such as hard fat or suitable
mixtures thereof. The compositions may additionally include lubricating agents, wetting agents, emulsifying agents, suspending agents, preserving agents, sweetening agents, flavouring agents, and the like. The
compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
The compositions are preferably formulated in a unit dosage form, eg. with each dosage containing from about 0.1 to about 500 mg of the active ingredient.
The precise dosage of the active compound to be administered and the length of the cause of treatment will, of course, depend on a number of factors including
for example, the age and weight of the patient, the specific condition requiring treatment and its severity, and the route of administration. Generally however, an effective dose may lie in the range of from about 0.01 mg/kg to about 20 mg/kg per day, eg from about 0.05 to about 10 mg/kg per day, preferably from about 0.2 to 1.0 mg/kg per day, administered one or more times per day. Thus for example, an appropriate daily dose for an adult, may be from 10 to 100 mg per day, eg 20 to 50 mg per day.
The administration may be by any suitable method known in the medicinal arts, including for example oral, parenteral (eg. intramuscular, subcutaneous,
intraperitoneal or intravenous) rectal or topical administration or administration by inhalation.
The invention will now be described in more detail by way of the following non-limiting Examples:
Formulation Example 1 - Hard gelatin capsules
Capsules are prepared using the following ingredients:
The active ingredient is selected from those shown in Table 1. The above ingredients are mixed and filled into hard gelatin capsules in 460 mg quantities.
Formulation Example 2
A tablet is prepared using the ingredients below:
The active ingredient is selected from those shown in Table 1. The components are blended and compressed to form tablets each weighing 665 mg.
The active compounds, selected from Table 1, is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30°C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder- of the propellant. The valve units are then fitted to the container.
Formulation Example 4
Tablets, each containing 60 mg of active ingredient, are made as follows:
The active ingredient (selected from Table 1), starch and cellulose are sieved and mixed thoroughly. The aqueous solution containing polyvinyl pyrrolidone is mixed with the resultant powder, and the mixture then is
passed again through a sieve. The granules so produced are dried at 50ºC and passed through a sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S.
sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.
Formulation Example 5
Suspensions, each containing 50 mg of active ingredient per ml dose, are made as follows:
The active ingredient (selected from Table 1), passed through a sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavour and colour are diluted with a portion of the water and added, with stirring.
Sufficient water is then added to produce the required volume.
Example 6
One female patient suffering from both fecal and urinary incontinence reported relief of the symptoms after treatment with buspirone.
The patient's fecal incontinence started immediately
after a delivery in 1987, after which the patient no longer felt the urge to defecate. Two years later the urinary incontinence started. The fecal incontinence was diagnosed as the result of a sensory nerve damage at the Department of neurology at the National hospital. The etiology of the urinary incontinence has not been found.
As a result of buspirone (Buspar) treatment of 40 mg per day, the patient's urinary incontinence improved
immediately. The patient's fecal incontinence improved after a period of 3-4 weeks, with a return of the patient's urge to defecate.
Example 7
One 40 year old, female patient suffering from migraine and bladder incontinence for many years, subjected to surgical intervention three times (stoma), and also suffering from an anxiety disorder, reported relief of these symptoms after treatment with buspirone.
As a result of buspirone treatment of 25 mg a day from 4th August 1992, the patient's anxiety was markedly improved. After 2-3 weeks, the following additive effects were noted:
The frequency of the patient's migraine attacks reduced (2 attacks during the last 4 months in comparison to approximately twice monthly prior to medication).
The patient's urinary incontinence, persistent since 1975, disappeared.
After 2 months treatment with buspirone was stopped,
whereafter the symptoms gradually relapsed. After 1 month the patient was once again treated with buspirone resulting in the same excellent effects.
Example 8
The patient is a 35 year old woman. In 1988 she was operated on for a prolaps of L5 in the columna. At the time of surgery she had urinary retention. Since then she has suffered continuously from low back pain, and irridiation pain from the L5/S1 area. She has been using a back cast, but with only temporary relief of her symptoms. A further operation is now being considered.
Since 1988 she has also had long periods with urinary problems. On occasion she has been incontinent, but mostly has suffered from urinary retention. She has been taught self-catherisation, and uses this when necessary. As a part of this routine she also measures her residual urine.
During a period in which the patient was experiencing urinary retention she was given buspirone at a dose of 30 mg a day. After two weeks of treatment she reported a reduction of residual urine, and soon no longer needed catherisation. Buspirone was administered for a total period of 4 months, without relapse of the patient's urinary symptoms.
About 6 months after the end of the 4 months buspirone administration period, she once again developed urinary retention and hence started self-c therisation. On administration of buspirone at the same dose as used previously, the patient once again experienced the same significant relief of her symptoms.
Claims
1. The use of a compound which interacts with 5-HT1A receptors, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for use in the treatment or prophylaxis of incontinence disorders.
2. The use as claimed in claim 1 wherein the compound is a 5-HT1A agonist, partial agonist or antagonist.
3. The use as claimed in claim 1 or 2 wherein the compound is selected from the list:
1) 2 -amino-1,2,3,3,4-tetrahydronaphthalenes and 3- amino chromanes;
2) 4 -amino-1,3,4,5-tetrahydrobenz- [c, d] indoles;
3) non-endogenous indoles;
4) aryloxy propanolamines;
5) benzodioxanes;
6) phenylcyclopropylamines;
7) piperidinylmethyl tetrahydroisoquinolines;
8) N-arylpiperazines;
9) piperazine derivatives,-
10) 1,1-diethyl-3-(8a-ergolinyl) urea derivatives; and
11) 2-amino-tetralines.
4. The use as claimed in any one of claims 1 to 3 wherein the compound is an azapirone, derivative or pharmaceutically acceptable salt thereof.
5. The use as claimed in claim 4 wherein the azapirone is buspirone or a pharmaceutically acceptable salt thereof.
6. The use as claimed in any one of claims 1 to 5 wherein the incontinence disorders are associated with conditions of the gastrointestinal or urogenital tracts.
7. The use as claimed in claim 6 wherein the
incontinence disorder is urinary incontinence, fecal incontinence or urinary retention.
8. The use as claimed in any one of claims 1 to 7 wherein the medicament contains the compound in an amount sufficient to administer an effective dose from about O.lmg/kg to about 20mg/kg.
9. The use as claimed in claim 8 wherein the effective dose is from about 0.05 to 10mg/kg.
10. A method of treatment of the human or non-human animal body to combat incontinence disorders, said method comprising administering to said body a compound interacting with 5-HT1A receptors, or a pharmaceutically acceptable salt thereof.
11. A method as claimed in claim 10 wherein the
compound is a 5-HT1A agonist, partial agonist or antagonist.
12. A method as claimed in claim 10 or 11 wherein the compound is selected from the list:
1) 2-amino-1,2,3,3,4-tetrahydronaphthalenes and 3- amino chromanes;
2) 4-amino-1,3,4,5-tetrahydrobenz- [c, d] indoles;
3) non-endogenous indoles;
4) aryloxy propanolamines;
5 ) benzodioxanes;
6) phenylcyclopropylamines;
7) piperidinylmethyl tetrahydroisoquinolines;
8) N-arylpiperazines;
9) piperazine derivatives;
10) 1,1-diethyl-3- (8a-ergolinyl) urea derivatives; and
11) 2-amino-tetralines.
13. A method as claimed in any one of claims 10 to 12 wherein the compound is an azapirone, derivative or pharmaceutically acceptable salt thereof.
14. A method as claimed in claim 13 wherein the
azapirone is buspirone or a pharmaceutically acceptable salt thereof.
15. A method as claimed in any one of claims 10 to 14 wherein the incontinence disorders are associated with conditions of the gastrointestinal or urogenital tracts.
16. A method as claimed in claim 15 wherein the
incontinence disorder is urinary incontinence, fecal incontinence or urinary retention.
17. A method as claimed in any one of claims 10 to 16 wherein said compound is administered at a dose of from about 0. lmg/kg to about 20mg/kg.
18. A method as claimed in claim 17 wherein the dose is from about 0.05 to 10mg/kg.
19. A pharmaceutical composition for use in the
treatment or prophylaxis of incontinence disorders, said composition comprising a compound interacting with 5- HT1A receptors or a pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 5, together with at least one pharmaceutically acceptable carrier, diluent or excipient.
20. A pharmaceutical composition as claimed in claim 19 wherein the incontinence disorders are associated with conditions of the gastrointestinal or urogenital tracts.
21. A pharmaceutical composition as claimed in claim 20 wherein the incontinence disorder is urinary incontinence, fecal incontinence or urinary retention.
22. A pharmaceutical composition as claimed in any one of claims 19 to 21 wherein the composition contains the compound in an amount sufficient to administer an effective dose from about 0.1mg/kg to about 20mg/kg.
23. A pharmaceutical composition as claimed in claim 22 wherein the effective dose is from about 0.05 to
10mg/kg.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU32637/95A AU3263795A (en) | 1994-08-23 | 1995-08-22 | Medicament for treatment or prophylaxis of incontinence |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9417135A GB9417135D0 (en) | 1994-08-23 | 1994-08-23 | Method |
GB9417135.2 | 1994-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996005817A1 true WO1996005817A1 (en) | 1996-02-29 |
Family
ID=10760357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1995/001995 WO1996005817A1 (en) | 1994-08-23 | 1995-08-22 | Medicament for treatment or prophylaxis of incontinence |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU3263795A (en) |
GB (1) | GB9417135D0 (en) |
WO (1) | WO1996005817A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997031637A1 (en) * | 1996-02-28 | 1997-09-04 | Recordati S.A., Chemical And Pharmaceutical Company | Use of 5-ht1a receptor antagonists for the treatment of urinary incontinence |
WO1998011888A1 (en) * | 1996-09-19 | 1998-03-26 | American Home Products Corporation | Method of treating urinary incontinence |
US5990114A (en) * | 1996-02-28 | 1999-11-23 | Recordati, S.A., Chemical And Pharmaceutical Company | Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence |
EP1010425A1 (en) * | 1997-08-19 | 2000-06-21 | Mitsubishi Chemical Industries Limited | Remedies for irritable bowel syndrome |
US6399614B1 (en) | 1997-08-01 | 2002-06-04 | Recordati S.A. Chemical And Pharmaceutical Company | 1-(N-phenylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring |
EP1266656A1 (en) * | 2000-03-01 | 2002-12-18 | American Pharmaceutical International | Anionic exchange polymer complexes of buspirone |
WO2003026564A2 (en) * | 2001-09-27 | 2003-04-03 | Pharmacia Ab | Pharmaceutical compositions for the treatment of urinary disorders |
US6894052B1 (en) | 1997-08-01 | 2005-05-17 | Recordati S.A. Chemical And Pharmaceutical Company | Diarylalkylpiperazines active on the lower urinary tract |
US8110688B2 (en) | 2005-05-11 | 2012-02-07 | Eisai R&D Management Co., Ltd. | Method for producing indole derivative having piperidine ring |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0558245A1 (en) * | 1992-02-25 | 1993-09-01 | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY | Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors |
-
1994
- 1994-08-23 GB GB9417135A patent/GB9417135D0/en active Pending
-
1995
- 1995-08-22 WO PCT/GB1995/001995 patent/WO1996005817A1/en active Application Filing
- 1995-08-22 AU AU32637/95A patent/AU3263795A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0558245A1 (en) * | 1992-02-25 | 1993-09-01 | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY | Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors |
Non-Patent Citations (2)
Title |
---|
A.LECCI ET AL.: "Involvement of 5-Hydroxytryptamine 1A Receptors in the Modulation of Micturition Reflexes in the Anesthetized Rat", J.PHARMACOL.EXP.THER., vol. 262, no. 1, pages 181 - 189 * |
B.L.HART ET AL.: "Effectiveness of buspirone on urine spraying and inappropiate urination in cats", J.AM.VET.MED.ASSOC., vol. 203, no. 2, 15 July 1993 (1993-07-15), pages 254 - 258 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997031637A1 (en) * | 1996-02-28 | 1997-09-04 | Recordati S.A., Chemical And Pharmaceutical Company | Use of 5-ht1a receptor antagonists for the treatment of urinary incontinence |
US5990114A (en) * | 1996-02-28 | 1999-11-23 | Recordati, S.A., Chemical And Pharmaceutical Company | Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence |
WO1998011888A1 (en) * | 1996-09-19 | 1998-03-26 | American Home Products Corporation | Method of treating urinary incontinence |
US6399614B1 (en) | 1997-08-01 | 2002-06-04 | Recordati S.A. Chemical And Pharmaceutical Company | 1-(N-phenylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring |
US6894052B1 (en) | 1997-08-01 | 2005-05-17 | Recordati S.A. Chemical And Pharmaceutical Company | Diarylalkylpiperazines active on the lower urinary tract |
EP1010425A1 (en) * | 1997-08-19 | 2000-06-21 | Mitsubishi Chemical Industries Limited | Remedies for irritable bowel syndrome |
EP1010425A4 (en) * | 1997-08-19 | 2002-12-04 | Mitsubishi Chem Ind | Remedies for irritable bowel syndrome |
US6596759B2 (en) | 1997-08-19 | 2003-07-22 | Mitsubishi Chemical Corporation | Medicament for treatment of irritable bowel syndrome |
EP1266656A1 (en) * | 2000-03-01 | 2002-12-18 | American Pharmaceutical International | Anionic exchange polymer complexes of buspirone |
WO2003026564A2 (en) * | 2001-09-27 | 2003-04-03 | Pharmacia Ab | Pharmaceutical compositions for the treatment of urinary disorders |
WO2003026564A3 (en) * | 2001-09-27 | 2003-12-11 | Pharmacia Ab | Pharmaceutical compositions for the treatment of urinary disorders |
US8110688B2 (en) | 2005-05-11 | 2012-02-07 | Eisai R&D Management Co., Ltd. | Method for producing indole derivative having piperidine ring |
Also Published As
Publication number | Publication date |
---|---|
GB9417135D0 (en) | 1994-10-12 |
AU3263795A (en) | 1996-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100342762B1 (en) | Pharmaceutical composition comprising substituted phenethylamine as active ingredient | |
Kohn et al. | Selected aspects of the clinical pharmacology of visceral analgesics and gut motility modifying drugs in the horse | |
US20040029941A1 (en) | Zonisamide use in obesity and eating disorders | |
HU218920B (en) | Use of duloxetine for preparing pharmaceutical compositions for treatment of incontinence | |
JPH0324447B2 (en) | ||
BRPI0609952A2 (en) | Methods to Modulate Bladder Function | |
RU2308268C2 (en) | Derivatives of aryl- or heteroarylazolyl carbinols for treating incontinence of urine | |
JPH0570343A (en) | Treating agent for affection of lower urinary tract | |
WO1996005817A1 (en) | Medicament for treatment or prophylaxis of incontinence | |
AU678149B2 (en) | 5-HT2 receptor antagonist compositions useful in treating venous conditions | |
EP1469853B1 (en) | Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-d-pyrimidine for treating of urinary incontinence | |
AU2003205836A1 (en) | Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2, 3-d)-pyrimidine for treating of urinary incontinence | |
JP2002265356A (en) | Agent for treating and/or preventing pain of lumbar vertebra herniated intervertebral disk | |
EP0506384A1 (en) | Pharmaceutical composition for the treatment of urinary incontinence containing DL- or L-threo-3-(3,4-dihydroxyphenyl)serine | |
AU2010212467A1 (en) | 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-D) pyrimidine in the treatment of functional bowel disorder | |
US7074834B2 (en) | Long acting, reversible veterinary sedative and analgesic and method of use | |
CA2491836C (en) | 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder | |
MX2011006852A (en) | 5-ht2a and 5-ht2b receptor antagonists for treating stenosis of the spinal canal. | |
ES2260160T3 (en) | TOPICAL COMPOSITION AND PROCEDURE TO TREAT URINARY INCONTINENCE OF EFFORT. | |
JPH01125330A (en) | Agent for increasing urethral pressure | |
Tom | A Randomised Clinical Trial To Compare Between The Effectiveness Of Dexmedetomidine And Fentanyl As Adjuvants In Spinal Anaesthesia | |
Watcha et al. | 9 Antiemetics | |
Yang et al. | Antiemetic Effect of Dexamethasone in Dogs Sedated with Xylazine | |
Friend | Antihypertensive drugs | |
EP1341777A2 (en) | 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatement of incontinence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |